These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20109135)

  • 1. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells.
    Zwirner NW; Croci DO; Domaica CI; Rabinovich GA
    Curr Pharm Des; 2010 Jan; 16(3):255-67. PubMed ID: 20109135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricking the balance: NK cells in anti-cancer immunity.
    Pahl J; Cerwenka A
    Immunobiology; 2017 Jan; 222(1):11-20. PubMed ID: 26264743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune mediators in cancer: between defense and resistance.
    Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
    Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune based therapies in cancer.
    Krüger C; Greten TF; Korangy F
    Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.
    Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD
    Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phagocytosis checkpoints as new targets for cancer immunotherapy.
    Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL
    Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
    Esposito A; Criscitiello C; Curigliano G
    Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.
    Hirohashi Y; Torigoe T; Inoda S; Takahashi A; Morita R; Nishizawa S; Tamura Y; Suzuki H; Toyota M; Sato N
    Immunotherapy; 2010 Mar; 2(2):201-11. PubMed ID: 20635928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
    Goldberg JL; Sondel PM
    Semin Oncol; 2015 Aug; 42(4):562-72. PubMed ID: 26320061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity.
    Wallace ME; Smyth MJ
    Springer Semin Immunopathol; 2005 Jun; 27(1):49-64. PubMed ID: 15729567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Natural Killer Cells for Improved Immunity and Control of the Adaptive Immune Response.
    Pierce S; Geanes ES; Bradley T
    Front Cell Infect Microbiol; 2020; 10():231. PubMed ID: 32509600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosurveillance and immunotherapy of tumors by innate immune cells.
    Iannello A; Thompson TW; Ardolino M; Marcus A; Raulet DH
    Curr Opin Immunol; 2016 Feb; 38():52-8. PubMed ID: 26686774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles for Innate Immunity in Combination Immunotherapies.
    Moynihan KD; Irvine DJ
    Cancer Res; 2017 Oct; 77(19):5215-5221. PubMed ID: 28928130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.